Handheld device to tell nerve tumors from normal tissue during surgery
Tests a handheld device that tells neurofibroma and MPNST tumors from normal tissue.
Plain-language title generated from the registry record
Registry title: DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Key facts
- Where
- Houston, United StatesSee the site
Where in United States
- The University of Texas M. D. Anderson Cancer CenterHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT07298083
- Record updated
- 18 September 2026
- Original description
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.Read full original descriptionShow less
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
The goal of this clinical research study is to learn if a handheld Mass Spectrometry device (MasSpec Pen) can accurately distinguish between masses, neurofibroma, and normal tissue during surgery.
Inclusion: This study will enroll approximately 60 participants diagnosed with either MPNST or neurofibroma who are undergoing surgical resection of an MPNST or neurofibroma as part of their standard of care; Age ≥ 1 years. Individuals younger than 18 years old will be included. For patients of age < 18 years, both parents' signatures will be requested; Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan, MRI, or calipers by clinical exam; Recurrent or primary disease; Patients who are > 18 years should have the ability to understand and the willingness to sign a written informed consent document; English and non-English speaking patients.
Exclusion: Patients who are pregnant and undergoing surgery for MPNST are not eligible; Adult patients with cognitive impairment requiring a legally authorized representative for consent; Patients under age 1 and neonates.